345 related articles for article (PubMed ID: 15489171)
1. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase.
Blanchard JE; Elowe NH; Huitema C; Fortin PD; Cechetto JD; Eltis LD; Brown ED
Chem Biol; 2004 Oct; 11(10):1445-53. PubMed ID: 15489171
[TBL] [Abstract][Full Text] [Related]
2. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
[TBL] [Abstract][Full Text] [Related]
3. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata.
Hamill P; Hudson D; Kao RY; Chow P; Raj M; Xu H; Richer MJ; Jean F
Biol Chem; 2006 Aug; 387(8):1063-74. PubMed ID: 16895476
[TBL] [Abstract][Full Text] [Related]
4. Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs.
Lin CW; Tsai CH; Tsai FJ; Chen PJ; Lai CC; Wan L; Chiu HH; Lin KH
FEBS Lett; 2004 Sep; 574(1-3):131-7. PubMed ID: 15358553
[TBL] [Abstract][Full Text] [Related]
5. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus.
Goetz DH; Choe Y; Hansell E; Chen YT; McDowell M; Jonsson CB; Roush WR; McKerrow J; Craik CS
Biochemistry; 2007 Jul; 46(30):8744-52. PubMed ID: 17605471
[TBL] [Abstract][Full Text] [Related]
6. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
7. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase.
Lai L; Han X; Chen H; Wei P; Huang C; Liu S; Fan K; Zhou L; Liu Z; Pei J; Liu Y
Curr Pharm Des; 2006; 12(35):4555-64. PubMed ID: 17168761
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.
Grum-Tokars V; Ratia K; Begaye A; Baker SC; Mesecar AD
Virus Res; 2008 Apr; 133(1):63-73. PubMed ID: 17397958
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.
Yang Q; Chen L; He X; Gao Z; Shen X; Bai D
Chem Pharm Bull (Tokyo); 2008 Oct; 56(10):1400-5. PubMed ID: 18827378
[TBL] [Abstract][Full Text] [Related]
10. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.
Wang L; Bao BB; Song GQ; Chen C; Zhang XM; Lu W; Wang Z; Cai Y; Li S; Fu S; Song FH; Yang H; Wang JG
Eur J Med Chem; 2017 Sep; 137():450-461. PubMed ID: 28624700
[TBL] [Abstract][Full Text] [Related]
11. Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay.
Kao RY; To AP; Ng LW; Tsui WH; Lee TS; Tsoi HW; Yuen KY
FEBS Lett; 2004 Oct; 576(3):325-30. PubMed ID: 15498556
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SARS-CoV 3CL protease by flavonoids.
Jo S; Kim S; Shin DH; Kim MS
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):145-151. PubMed ID: 31724441
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.
Ghosh AK; Takayama J; Aubin Y; Ratia K; Chaudhuri R; Baez Y; Sleeman K; Coughlin M; Nichols DB; Mulhearn DC; Prabhakar BS; Baker SC; Johnson ME; Mesecar AD
J Med Chem; 2009 Aug; 52(16):5228-40. PubMed ID: 19645480
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
[TBL] [Abstract][Full Text] [Related]
15. "Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs.
Rajnarayanan RV; Dakshanamurthy S; Pattabiraman N
Biochem Biophys Res Commun; 2004 Aug; 321(2):370-8. PubMed ID: 15358186
[TBL] [Abstract][Full Text] [Related]
16. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.
Paul A; Sarkar A; Saha S; Maji A; Janah P; Kumar Maity T
Bioorg Med Chem; 2021 Sep; 46():116301. PubMed ID: 34332853
[TBL] [Abstract][Full Text] [Related]
17. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.
Kilianski A; Mielech AM; Deng X; Baker SC
J Virol; 2013 Nov; 87(21):11955-62. PubMed ID: 23986593
[TBL] [Abstract][Full Text] [Related]
18. Drug design targeting the main protease, the Achilles' heel of coronaviruses.
Yang H; Bartlam M; Rao Z
Curr Pharm Des; 2006; 12(35):4573-90. PubMed ID: 17168763
[TBL] [Abstract][Full Text] [Related]
19. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays.
Chen L; Chen S; Gui C; Shen J; Shen X; Jiang H
J Biomol Screen; 2006 Dec; 11(8):915-21. PubMed ID: 17092912
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
